Fig. 5

CSE treatment stimulates proliferation of human PASMCs, and celecoxib, beraprost sodium and daltroban inhibit the proliferation. (A) confluent human PASMCs were treated with or without CSE for up to 72 h, and then WST-1 assay was conducted. (B–D) confluent human PASMCs were pre-treated with or without different concentrations of celecoxib (B), beraprost sodium (C) and daltroban (D) for 1 h before being treated with CSE for 24 h. WST-1 was then conducted. Data are expressed as relative proliferation (% change over control). Each data point represents mean ± SEM from three independent experiments using PASMCs from three different donors. *P < 0.05, ***P < 0.001 compared with control; ⁺P < 0.05, ⁺⁺P < 0.01, ⁺⁺⁺P < 0.001 compared with CSE alone